Brief: Ventyx Biosciences Announces Positive Results From The Phase 2 Trial Of Vtx002 In Patients With Moderate-To-Severely Active Ulcerative Colitis

Ventyx Biosciences

09/10/2023 21:03

Oct 9 (Reuters) - Ventyx Biosciences Inc  VTYX.O :
    * VENTYX BIOSCIENCES ANNOUNCES POSITIVE RESULTS FROM THE
PHASE 2
TRIAL OF VTX002 IN PATIENTS WITH MODERATE-TO-SEVERELY ACTIVE
ULCERATIVE COLITIS
    * VENTYX BIOSCIENCES INC - BOTH 30 MG AND 60 MG DOSES OF
VTX002
DEMONSTRATED AN EXCELLENT SAFETY AND TOLERABILITY PROFILE
    * VENTYX BIOSCIENCES INC - VTX002 60 MG ACHIEVED PRIMARY
ENDPOINT
OF CLINICAL REMISSION WITH A HIGH RATE OF COMPLETE ENDOSCOPIC
REMISSION
    * VENTYX BIOSCIENCES INC: VTX002 WAS WELL TOLERATED IN BOTH
DOSE
COHORTS, WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS
OBSERVED

Source text for Eikon:  ID:nGNX7jyJxt 
Further company coverage:  VTYX.O 

 ((Reuters.Briefs@thomsonreuters.com;))